You are here
Management of Targeted Therapies: PD1 in lung cancer
By Richard Gralla, recorded at TAO (Transatlantic Oncology meeting), Nov 20-21, 2014, Paris
In his presentation, Richard Gralla reviews new approaches to treating non-small-cell lung cancer and puts the PD-1 pathway into context. Nowadays, there are at least three distinct treatment strategies: chemotherapy, genetic abnormalities such as mutations or rearrangements and immune checkpoint inhibition. Outcomes differ, for example, according to smoking status and gender. Newer pathways have the potential to identify individual patients likely to respond to treatment. However, chemotherapy remains the largest contributor to survival benefit for the whole population.
Richard Gralla, A. Einstein School of Medicine, NY, USA